Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Fineline Cube Jan 10, 2026
Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026
Company Deals

Viva Biotech and CMS Forge AI-Powered Drug Development Alliance

Fineline Cube Jan 8, 2026
Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity

Fineline Cube Jan 10, 2026
Company Drug

Lilly’s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis

Fineline Cube Jan 10, 2026
Company Deals

Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics

Fineline Cube Dec 14, 2022

UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into...

Company Deals

Henlius Biotech Partners with Medilink for Global ADC Development

Fineline Cube Dec 14, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining...

Company Drug

Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study

Fineline Cube Dec 14, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...

Company Medical Device

Lifetech Scientific Completes Enrollment for IBS Coronary Stent Phase II Study

Fineline Cube Dec 14, 2022

China-based Lifetech Scientific Corporation (HKG: 1302) announced that all patients have been enrolled in a...

Policy / Regulatory

China’s COVID-19 Vaccination Second Booster Shot Plan Released

Fineline Cube Dec 14, 2022

The National Health Commission website indicates that the COVID-19 Joint Prevention and Control Mechanism of...

Company Drug

ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval

Fineline Cube Dec 14, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...

Company Drug

Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial

Fineline Cube Dec 14, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of...

Company Drug

Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting

Fineline Cube Dec 14, 2022

China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...

Company Medical Device

Cryofocus Biotechnology’s RDN System Gains FDA Breakthrough Therapy Designation

Fineline Cube Dec 14, 2022

Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd’s in-house developed Cryofocus RDN System, a...

Policy / Regulatory

Beijing Releases COVID-19 Infection Drug List to Address Stocking Issues

Fineline Cube Dec 13, 2022

The Beijing Municipal Health Commission formulated and released the “COVID-19 infection drug list” (first edition),...

Company Deals

Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to...

Policy / Regulatory

China’s State Council Boosts Internet Medical Services Amid COVID-19

Fineline Cube Dec 13, 2022

The State Council released a notification in relation to the COVID-19 pandemic, seeking to ramp...

Company Drug

Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202

Fineline Cube Dec 13, 2022

China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...

Company Drug

Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone

Fineline Cube Dec 13, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...

Company Drug

Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment

Fineline Cube Dec 13, 2022

China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I...

Company Deals

Yantai Dongcheng to Acquire US Firm XingImaging for $30.2M

Fineline Cube Dec 13, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) is set to acquire a 100%...

Company Medical Device

Hotgen Biotech’s COVID-19 Antigen Home Test Approved in Russia

Fineline Cube Dec 13, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) announced receiving market approval in Russia for its...

Company Drug

Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting

Fineline Cube Dec 13, 2022

China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study...

Company R&D

ClinBrain and WCH Establish Joint Laboratory for Geriatric Information Platform

Fineline Cube Dec 13, 2022

Shanghai-based ClinBrain, a clinical data repository (CDR) and medical big data services provider, together with...

Company Deals

Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...

Posts pagination

1 … 527 528 529 … 606

Recent updates

  • InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
  • MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal
  • Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity
  • Lilly’s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis
  • NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Company Drug

Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity

Company Drug

Lilly’s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.